Insider Activity: Phillip Frost Reports Major OPK Holdings via Trusts
Rhea-AI Filing Summary
Phillip Frost, M.D., in his capacities as CEO & Chairman, director and reported 10% owner, disclosed multiple changes in his OPKO Health (OPK) holdings. The filing shows on 08/08/2025 a purchase of 675,000 shares at $1.32 per share and a reported disposition of 3,568,951 shares. Following the reported transactions the Form lists indirect beneficial ownership amounts of 214,676,448 shares and 30,127,177 shares, each referenced to separate footnotes.
The footnotes explain these shares are held through Frost-controlled entities and trusts (Frost Gamma Investments Trust and Frost Nevada Investments Trust) with Dr. Frost acting as trustee or related party; the filing states he disclaims beneficial ownership except to the extent of any pecuniary interest. The report is a Section 16 Form 4 disclosure of insider activity and trust relationships only.
Positive
- Insider purchase of 675,000 OPK shares at $1.32, indicating additional direct acquisition activity by the reporting parties
- Detailed trust disclosures clarify ownership pathways through Frost Gamma and Frost Nevada entities
Negative
- Disposition of 3,568,951 OPK shares by the reporting person was also reported, representing a substantial sale
- Large indirect holdings (214,676,448 and 30,127,177 shares) may complicate assessments of direct insider alignment due to trust structures and disclaimers
Insights
TL;DR: Insider both purchased and sold OPK shares on 08/08/2025; transactions total a 675,000 share buy at $1.32 and a 3,568,951 share disposition.
The filing documents an intra-day or same-date set of transactions comprising a purchase (code P) of 675,000 shares at $1.32 and a separate reported disposition of 3,568,951 shares. These are explicit, non-derivative equity changes reported under Section 16. From an investor-information perspective this is mixed signaling because the insider executed both buy and sell activity and maintains very large indirect stakes. The filing does not provide timing detail beyond the transaction date, nor does it state the purpose of the transactions.
TL;DR: Dr. Frost’s holdings are routed through related trusts and entities; the filing contains detailed disclaimers about beneficial ownership.
The footnotes explicitly state shares are held by Frost Gamma Investments Trust and Frost Nevada Investments Trust, with Dr. Frost serving as trustee and related entities as beneficiaries or general partners. The report includes standard Section 16 disclaimers that he disclaims beneficial ownership except for any pecuniary interest. This structure is clearly documented in the filing and is material to understanding the form of his reported indirect ownership.